Press Releases Items Per Page 102550 Year None2018201720162015201420132012201120102007 03.20.14 ECOG-ACRIN Opens Phase III Trial of Syndax?s Entinostat in Advanced Breast Cancer 02.13.14 Syndax Announces NCI and FDA Reach Agreement on a Special Protocol Assessment (SPA) for the Phase 3 Trial of Entinostat in Patients with Advanced ER+ Breast Cancer 02.03.14 Leading Breast Cancer Expert, George W. Sledge, Jr., M.D., Joins Syndax as an Independent Director 01.23.14 Syndax Announces Appointment of Richard P. Shea as Independent Director and Chair of the Audit Committee 11.01.13 Syndax Promotes John S. Pallies to Chief Financial Officer and Dr. Peter Ordentlich to Chief Technology Officer 09.11.13 Syndax’s Entinostat Receives Breakthrough Therapy Designation from FDA for Treatment of Advanced Breast Cancer 09.04.13 Syndax and Eddingpharm Enter into a License Agreement Giving Eddingpharm Rights to Commercialize Entinostat in China and Other Asian Countries 08.27.13 Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers 05.14.13 Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer 05.09.13 Syndax Pharmaceuticals to Commercialize First-in-Class Lung Cancer Treatment Developed at the University of Colorado 05.29.12 Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO 05.16.12 Syndax Pharmaceuticals Appoints Luke Evnin, Ph.D. to Board of Directors Pagination First page « first Previous page ‹ previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 Next page next › Last page last »
02.13.14 Syndax Announces NCI and FDA Reach Agreement on a Special Protocol Assessment (SPA) for the Phase 3 Trial of Entinostat in Patients with Advanced ER+ Breast Cancer
02.03.14 Leading Breast Cancer Expert, George W. Sledge, Jr., M.D., Joins Syndax as an Independent Director
01.23.14 Syndax Announces Appointment of Richard P. Shea as Independent Director and Chair of the Audit Committee
11.01.13 Syndax Promotes John S. Pallies to Chief Financial Officer and Dr. Peter Ordentlich to Chief Technology Officer
09.11.13 Syndax’s Entinostat Receives Breakthrough Therapy Designation from FDA for Treatment of Advanced Breast Cancer
09.04.13 Syndax and Eddingpharm Enter into a License Agreement Giving Eddingpharm Rights to Commercialize Entinostat in China and Other Asian Countries
08.27.13 Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
05.14.13 Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
05.09.13 Syndax Pharmaceuticals to Commercialize First-in-Class Lung Cancer Treatment Developed at the University of Colorado
05.29.12 Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
